Vadadustat FDA Approval Status
Last updated by Judith Stewart, BPharm on March 31, 2021.
FDA Approved: No
Generic name: vadadustat
Company: Akebia Therapeutics, Inc.
Treatment for: Anemia Associated with Chronic Renal Failure
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia due to chronic kidney disease (CKD) in adults.
Development timeline for vadadustat
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.